May 13, 2019 Stephen Copeman

Improvements in the delivery of CAR-T cell therapy

Ways to prevent or reduce the severity of “cytokine release syndrome” (CRS) have been found, and are now routinely implemented as part of care for patients. When first developed, CRS was the major complication of CAR-T cell therapy – often affecting the lungs.

It is also clear that the risk of neurological complications of CAR-T cell therapy can be greatly reduced, by treating patients who have received fewer “lines” of chemotherapy first, and by selecting the target protein for CAR-T cells carefully.

Most patients who receive CAR-T cell therapy should now expect to spend little time in hospital after the therapy – although there are still some small risks of major complications.